Cempra (CEMP) Shares are Down -2.11%

Cempra (CEMP) has risen sharply, recording gains of 3.85% in the past 4 weeks. However, the stock has corrected -2.11% in the past 1 week, providing a good buying opportunity on dips. Cempra (CEMP) : During the past 4 weeks, traders have been relatively bearish on Cempra (CEMP), hence the stock is down -2.72% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.71% relative to the S&P 500.

Cempra (NASDAQ:CEMP): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $18.00 and $17.55 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $18.24. The buying momentum continued till the end and the stock did not give up its gains. It closed at $18.08, notching a gain of 1.40% for the day. The total traded volume was 741,002 . The stock had closed at $17.83 on the previous day.


The stock has recorded a 20-day Moving Average of 2.68% and the 50-Day Moving Average is 2.69%. Cempra, Inc. has dropped 5.83% during the last 3-month period . Year-to-Date the stock performance stands at -41.92%.

Cempra Inc. is a clinical-stage pharmaceutical company focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Companys lead product, solithromycin, is being developed in oral capsules, intravenous, or IV, and suspension formulations, initially for the treatment of community acquired bacterial pneumonia, or CABP, an infection of the respiratory tract. The Companys second product is Taksta, an antibiotic known as fusidic acid, that has been used for decades outside the United States, including Western Europe, but , which has never been approved in the United States. The Company is developing Taksta in the United States as an oral treatment of refractory bone and joint infections caused by staphylococci.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.